Incyte Corporation INCY
123.36
(1.46)
(1.17%)
as of 29 Sep
- Market cap
- $26.1B
- P/E
- 15.4×
Follow INCY
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Incyte Corporation (INCY) Free cash flow margin
Incyte Corporation's free cash flow margin over the twelve months to 30 June 2026 was 32.5%, up 6.6 percentage points from fiscal 2025 (25.9%). Over the past ten years it has ranged from −13.3% (fiscal 2017) to 29.3% (fiscal 2019); the current reading is higher than 82% of that period. That is above the Biotechnology industry median of 0.00% and above the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Annual
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2025 | 25.9% | 20.32 |
| FY2024 | 5.54% | (6.61) |
| FY2023 | 12.2% | (14.13) |
| FY2022 | 26.3% | 7.24 |
| FY2021 | 19.0% | 30.74 |
| FY2020 | −11.7% | (41.00) |
| FY2019 | 29.3% | 15.34 |
| FY2018 | 14.0% | 27.24 |
| FY2017 | −13.3% | (29.96) |
| FY2016 | 16.7% | 8.27 |
Against its own ten years
Low −13.3%
High 29.3%
Ten-year median
14.0%
Current reading's percentile
82
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| RPRX Royalty Pharma PLC compare | 51.7% |
| INCY Incyte Corporation | 32.5% |
| JAZZ Jazz Pharmaceuticals PLC compare | 30.8% |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 21.7% |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 17.1% |
| BNTX BioNTech SE Sponsored ADR compare | 16.6% |
| INSM Insmed, Inc. compare | −71.0% |
| GMAB Genmab A/S Sponsored ADR compare | −153.6% |
| ROIV Roivant Sciences Ltd. compare | −10,901.0% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue
More on INCY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement